Immunovant, Inc. (IMVT)
NASDAQ: IMVT · IEX Real-Time Price · USD
28.80
+0.19 (0.66%)
Apr 24, 2024, 4:00 PM EDT - Market closed
Company Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 164 |
| CEO | Dr. Peter Salzmann M.B.A., M.D. |
Contact Details
Address: 320 West 37th Street New York, New York 10018 United States | |
| Phone | 917-580-3099 |
| Website | immunovant.com |
Stock Details
| Ticker Symbol | IMVT |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001764013 |
| CUSIP Number | 45258J102 |
| ISIN Number | US45258J1025 |
| Employer ID | 83-2771572 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
| Dr. Peter Salzmann M.B.A., M.D. | Chief Executive Officer and Director |
| Eva Renee Barnett M.B.A. | Chief Financial Officer |
| Dr. William L. Macias M.D., Ph.D. | Chief Medical Officer |
| Dr. Jay S. Stout Ph.D. | Chief Technology Officer |
| Dr. Chau Cheng M.B.A., Ph.D. | Vice President of Investor Relations |
| Mark S. Levine | Chief Legal Officer and Corporate Secretary |
| Lauren Schrier M.B.A. | Vice President of Marketing |
| Christine Blodgett | Vice President of Human Resources |
| Dr. Julia G. Butchko Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2024 | UPLOAD | Filing |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | 10-Q | Quarterly Report |
| Feb 12, 2024 | 8-K | Current Report |
| Feb 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 17, 2024 | UPLOAD | Filing |
| Jan 9, 2024 | 8-K | Current Report |
| Dec 20, 2023 | 8-K | Current Report |
| Dec 1, 2023 | 144 | Filing |